Senseonics Holdings, Inc. highlighted new clinical data presented at the American Diabetes Association 83rd Scientific Session. Two studies were presented demonstrating the safety and accuracy of the Eversense E3 CGM system. A feasibility study was conducted in 32 patients using a modified Eversense CGM System to assess if longevity could be extended through 365 days while maintaining accuracy.

The key findings were as follows: Sensor longevity was 97% through 365 days; The sensor was safe with few minor skin irritation adverse events; MARD observed for the modified CGM system through 365 days was similar to that observed with Eversense E3 C GM System through 180 days. The feasibility study of the next generation Eversense Sensor showed the system could provide accurate performance through a 365-day period. In this multi-center study, CGM naive patients were followed for 6 months of self-monitoring of blood glucose (SMBG) followed by 6 months of Eversense CGM System use (90-day Eversense transitioning to Eversense E3 CM System after FDA approval).

Changes in glucometrics and HbA1c were evaluated. In the first 100 patients who completed the study, the key results of the use of Eversense CGM for 6 months were the following: While there was a decrease in HbA1c after 6 months of SMBG use, there was a further significant reduction after 6 months of Eversense E3 CG to a mean value of 6.93% CGM use resulted in a significant increase in time in range (70-180 mg/dL) to a mean of 74.2% There were significant decreases in both time below range (180 mg/dL and >250 mg/dL); 68% of patients achieved >70% TIR by the end of the CGM phase. This study, reporting on 100 adult patients with diabetes, showed that superior glucose outcomes were achieved with 6 months use of Eversense C GM compared to the initial 6-month period where management was achieved with SMBG only.